When Seeking ‘Breakthrough’ Status, Beware Of Manufacturing Changes

Clinical data supporting a designation request should come from a product under development, not from a study using an earlier formulation, CBER reps say. Rolling submissions help ensure that potential manufacturing and facility concerns are identified early.